Volume 7.19 | May 17

Hematopoiesis News 7.19 May 17, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Transplantation Dose Alters the Differentiation Program of Hematopoietic Stem Cells
Researchers found that, in the long term following transplantation, 70%–80% of donor-hematopoietic stem cell (HSC)-derived clones do not produce all measured blood cell types. High HSC doses lead to more clones that exhibit balanced lymphocyte production, whereas low doses produce more T-cell-specialized clones. [Cell Rep] Full Article | Graphical Abstract
Get More of the Cells You Need with StemSpan™ Megakaryocyte Expansion Supplement and StemSpan™ SFEM
 
PUBLICATIONS (Ranked by impact factor of the journal)
Single Targeted Exon Mutation Creates a True Congenic Mouse for Competitive Hematopoietic Stem Cell Transplantation: The C57BL/6-CD45.1STEM Mouse
Scientists demonstrated that a single amino acid change determines the CD45.1 epitope. Further, they report on the single targeted exon mutant (STEM) mouse strain, CD45.1STEM, which is functionally equivalent to CD45.2 cells in competitive bone marrow transplants. [Stem Cell Reports] Full Article | Graphical Abstract

High Levels of Canonical Wnt Signaling Lead to Loss of Stemness and Increased Differentiation in Hematopoietic Stem Cells
In the blood system, the role of Wnt signaling has been the subject of much debate but there is consensus that high Wnt signals lead to loss of reconstituting capacity. To better understand this phenomenon, the authors have taken advantage of a series of hypomorphic mutant Apc alleles resulting in a broad range of Wnt dosages in hematopoietic stem cells and performed whole-genome gene expression analyses. [Stem Cell Reports] Full Article

Expression of CDKN1C in the Bone Marrow of Patients with Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Is Associated with Poor Survival after Conventional Chemotherapy
Investigators tested the hypothesis that proliferative activity of hematopoietic stem cells has impact on survival in newly diagnosed patients with myelodysplastic syndrome and secondary acute myeloid leukemia. [Int J Cancer] Abstract

Calreticulin-Mutant Proteins Induce Megakaryocytic Signaling to Transform Hematopoietic Cells and Undergo Accelerated Degradation and Golgi-Mediated Secretion
Researchers demonstrated the potency of calreticulin mutants to drive expression of megakaryocytic differentiation markers such as NF-E2 and CD41 as well as thrombopoietin receptor. [J Hematol Oncol] Full Article

Repression of Primitive Erythroid Program Is Critical for the Initiation of Multi-Lineage Hematopoiesis in Mouse Development
Investigators found that the earliest committed hematopoietic progenitors highly expressed Gata1, Scl/tal1, and Klf1 genes. Expression of these transcription factors, which is known to form a core erythroid transcriptional network, explained the prompt generation of primitive erythrocytes from these earliest progenitors. [J Cell Physiol] Abstract

MLL1 and MLL1 Fusion Proteins Have Distinct Functions in Regulating Leukemic Transcription Program
The authors demonstrated that mixed lineage leukemia protein-1 (MML1), probably through C-terminal interaction with WDR5, is recruited to regulatory enhancers that are enriched for binding sites of E-twenty-six family transcription factors, whereas MLL-AF9 binds to chromatin regions that have no H3K4me1 enrichment. [Cell Disc] Abstract

CLINICAL RESEARCH

Phase II Study of Intensified Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Acute Lymphoblastic Leukemia
Scientists determined the efficacy of an intensified, multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients older than 50 years. [Cancer] Abstract

Busulfan, Melphalan, and Bortezomib versus High Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
The authors compared a novel conditioning combination incorporating busulfan, melphalan and bortezomib versus standard melphalan 200 mg/m2 in newly diagnosed patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. [Biol Blood Marrow Transplant] Abstract

Filgrastim-Stimulated Bone Marrow Compared to Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study
Researchers conducted a Phase III, open label, multicenter randomized trial of 230 adults with hematologic malignancies receiving allografts from siblings after myeloablative conditioning to compare filgrastim-mobilized peripheral blood and filgrastim-stimulated marrow. [Biol Blood Marrow Transplant] Abstract

Register Now for our Live Webinar- Anticipating Cytopenia: In Vitro Methods for Assessing Hematotoxicity
 
REVIEWS
Long Non-Coding RNAs in Normal and Malignant Hematopoiesis
Besides their role in normal cellular physiology, accumulating evidence has linked lncRNA expression and functions to cancer development and progression. The authors summarize and discuss what is known about their expression and roles in hematopoiesis with a particular focus on their cell-type specificity, functional interactions, and involvement in the pathobiology of hematological malignancies. [Oncotarget] Full Article

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
The authors summarize the encouraging early results seen with the regimens and discuss two hurdles that need to be overcome for achieving even greater success, disease relapse and graft-versus-host disease. [Haematologica] Full Article

DNA Methylation in Hematopoietic Development and Disease
The authors review some of the recent literature regarding the role of DNA methylation in hematopoietic health and disease. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
 
INDUSTRY NEWS
Arkin Holdings and Primera Capital Lead an Investment of $13 Million in BioSight for an Innovative Treatment of Acute Leukemia
BioSight, Ltd announced the closing of an investment of $13 million led by the Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. [BioSight, Ltd (PR Newswire Association LLC.)] Press Release

HemaCare Signs Distribution Agreement with China-Based Partner
HemaCare Corporation has expanded its global capabilities through a strategic distribution agreement in China with Shanghai-based MT-Biological Science and Technology Co. Ltd. This partnership ensures researchers in China can access HemaCare’s human healthy and disease state cryopreserved hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support. [HemaCare Corporation] Press Release

ArcherDX Launches NGS Assays for Hematological Malignancy Profiling
ArcherDX, Inc., announced three new targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations and relative expression levels in myeloid and lymphoid origin malignancies. [ArcherDX, Inc. (Business Wire)] Press Release

From our sponsor:
Quickly find the whole-blood frequencies of human and mouse immune cell types.
Download the app.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 24th Biennial European Association for Cancer Research (EACR) Congress
July 9-16, 2016
Manchester, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

NEW Technical Sales Representative (STEMCELL Technologies Inc.)

NEW Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Scientist – Hematology (STEMCELL Technologies Inc.)

PhD Student – Leukemia Biology (Helmholtz Association)

Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us